ASCO24 Updates: Dr. Hiroyuki Uetake on Biomarkers from the Paradigm Trial in Colorectal Cancer

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Dr. Hiroyuki Uetake shared insights on ‘Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.‘

This is Hiroyuki Uetake from Japan. I presented yesterday in the oral presentation of colorectal cancer that the result of a biomarker study of paradigm phase 3 trial that compares panitumumab versus bevacizumab for metastatic colon cancer. The biomarker study was done and in this presentation I said that some biomarker works after the treatment.

After the first line treatment of metastatic colorectal cancer in paradigm, we tested the liquid biopsy and we found that after panitumumab administration, RTK-RAS pathway was emerged and after the treatment of bevacizumab, CIMP pathway emerged and those emerged resulted in poor survival of each treatment. I mean poor overall survival and poor post-progression survival. So we can say that the liquid biopsy after the first line treatment works.

More videos and content from ASCO 2024 on OncoDaily.